180 related articles for article (PubMed ID: 38391964)
1. The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-PD-1 sdAb for Osteosarcoma Treatment
Higgins TA; Patton DJ; Shimko-Lofano IM; Eller TL; Molinari R; Sandey M; Ismail A; Smith BF; Agarwal P
Cells; 2024 Feb; 13(4):. PubMed ID: 38391964
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer.
Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Curiel DT
J Ovarian Res; 2016 Jun; 9(1):38. PubMed ID: 27349517
[TBL] [Abstract][Full Text] [Related]
3. Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory.
Martinez-Velez N; Laspidea V; Zalacain M; Labiano S; García-Moure M; Puigdelloses M; Marrodan L; Gonzalez-Huarriz M; Herrador G; de la Nava D; Ausejo-Mauleon I; Fueyo J; Gomez-Manzano C; Patiño-García A; Alonso MM
Mol Cancer Ther; 2022 Mar; 21(3):471-480. PubMed ID: 34965961
[TBL] [Abstract][Full Text] [Related]
4. Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells.
Le LP; Rivera AA; Glasgow JN; Ternovoi VV; Wu H; Wang M; Smith BF; Siegal GP; Curiel DT
Gene Ther; 2006 Mar; 13(5):389-99. PubMed ID: 16292351
[TBL] [Abstract][Full Text] [Related]
5. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
González-Pastor R; Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Lu ZH; Goedegebuure SP; Podhajcer OL; Curiel DT
J Ovarian Res; 2019 Feb; 12(1):18. PubMed ID: 30767772
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
7. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
8. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
[TBL] [Abstract][Full Text] [Related]
9. Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo.
Witlox AM; Van Beusechem VW; Molenaar B; Bras H; Schaap GR; Alemany R; Curiel DT; Pinedo HM; Wuisman PI; Gerritsen WR
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):61-7. PubMed ID: 14734452
[TBL] [Abstract][Full Text] [Related]
10. Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases.
Graat HC; van Beusechem VW; Schagen FH; Witlox MA; Kleinerman ES; Helder MN; Gerritsen WR; Kaspers GJ; Wuisman PI
Mol Cancer; 2008 Jan; 7():9. PubMed ID: 18215325
[TBL] [Abstract][Full Text] [Related]
11. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity.
Mei S; Peng S; Vong EG; Zhan J
Int Immunopharmacol; 2024 Feb; 128():111579. PubMed ID: 38278066
[TBL] [Abstract][Full Text] [Related]
12. Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.
Graat HC; Witlox MA; Schagen FH; Kaspers GJ; Helder MN; Bras J; Schaap GR; Gerritsen WR; Wuisman PI; van Beusechem VW
Br J Cancer; 2006 Jun; 94(12):1837-44. PubMed ID: 16736005
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma.
Wedekind MF; Cripe TP
Adv Exp Med Biol; 2020; 1258():77-89. PubMed ID: 32767235
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
Clubb JHA; Kudling TV; Heiniö C; Basnet S; Pakola S; Cervera Carrascón V; Santos JM; Quixabeira DCA; Havunen R; Sorsa S; Zheng V; Salo T; Bäck L; Aro K; Tulokas S; Loimu V; Hemminki A
Front Immunol; 2022; 13():794251. PubMed ID: 35355980
[TBL] [Abstract][Full Text] [Related]
15. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
Clubb JHA; Kudling TV; Girych M; Haybout L; Pakola S; Hamdan F; Cervera-Carrascon V; Hemmes A; Grönberg-Vähä-Koskela S; Santos JM; Quixabeira DCA; Basnet S; Heiniö C; Arias V; Jirovec E; Kaptan S; Havunen R; Sorsa S; Erikat A; Schwartz J; Anttila M; Aro K; Viitala T; Vattulainen I; Cerullo V; Kanerva A; Hemminki A
Front Immunol; 2023; 14():1060540. PubMed ID: 36817448
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.
Thaci B; Ahmed AU; Ulasov IV; Tobias AL; Han Y; Aboody KS; Lesniak MS
Cancer Gene Ther; 2012 Jun; 19(6):431-42. PubMed ID: 22555507
[TBL] [Abstract][Full Text] [Related]
18. Administration of a conditionally replicative oncolytic canine adenovirus in normal dogs.
Smith BF; Curiel DT; Ternovoi VV; Borovjagin AV; Baker HJ; Cox N; Siegal GP
Cancer Biother Radiopharm; 2006 Dec; 21(6):601-6. PubMed ID: 17257075
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic viruses for potential osteosarcoma therapy.
Hingorani P; Sampson V; Lettieri C; Kolb EA
Adv Exp Med Biol; 2014; 804():259-83. PubMed ID: 24924179
[TBL] [Abstract][Full Text] [Related]
20. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.
Hasei J; Sasaki T; Tazawa H; Osaki S; Yamakawa Y; Kunisada T; Yoshida A; Hashimoto Y; Onishi T; Uno F; Kagawa S; Urata Y; Ozaki T; Fujiwara T
Mol Cancer Ther; 2013 Mar; 12(3):314-25. PubMed ID: 23315976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
